Cellebrite DI (CLBT)
Official siteTECHNOLOGY • SOFTWARE - INFRASTRUCTURE • NASDAQ
Market Cap: $2.90B
Last updated: Nov 17, 2026 at 11:05 AM ET
Cellebrite DI (CLBT) Stock Forecast
Analysts expect Cellebrite DI (CLBT) to earn $0.58 per share in the fiscal year ending Dec 31, 2026, on revenue of $555.84M. Of 8 analysts, 8 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 4 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 25.0% |
| Buy | 6 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 13.8% and revenue estimates rise 13.2%.
- Fiscal year ending Dec 31, 2026
- $0.58
- EPS consensus, revenue $555.84M
- Fiscal year ending Dec 31, 2027
- $0.66
- EPS consensus, revenue $629.48M
- Next report
- Feb 9, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.58 | $0.56 to $0.60 | 8 | $555.84M | $554.00M to $558.28M | 8 |
| Dec 31, 2027 | $0.66 | $0.53 to $0.73 | 8 | $629.48M | $612.00M to $649.91M | 8 |
Quarterly Estimates
The EPS consensus falls from $0.18 for the quarter ending Dec 31, 2026 to $0.14 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.18 | $0.16 to $0.20 | 10 | $149.93M | $142.10M to $157.50M | 10 |
| Mar 31, 2027 | $0.14 | $0.12 to $0.17 | 6 | $145.61M | $142.00M to $152.65M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 8 upward and 9 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 4 |
| Fiscal year ending Dec 31, 2027 | 3 | 4 |
| Quarter ending Mar 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 5.5% from $0.55.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.58 | $0.55 | $0.55 | $0.55 | $0.55 | +6.1% |
| Fiscal year ending Dec 31, 2027 | $0.66 | $0.65 | $0.65 | $0.65 | $0.65 | +1.1% |
| Quarter ending Mar 31, 2027 | $0.14 | $0.14 | $0.14 | $0.14 | $0.14 | +4.1% |
Frequently Asked Questions About CLBT
What is the CLBT stock forecast?
Consensus analyst estimates put Cellebrite DI's EPS at $0.58 for the fiscal year ending Dec 31, 2026, on revenue of $555.84M. The consensus rating from 8 analysts is Buy.
How do analysts rate CLBT stock?
Of 8 analysts covering Cellebrite DI, 2 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CLBT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.58, with estimates from $0.56 to $0.60 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.66, with estimates from $0.53 to $0.73 from 8 analysts.
What revenue do analysts expect from Cellebrite DI next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $555.84M, with estimates from $554.00M to $558.28M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $629.48M, with estimates from $612.00M to $649.91M.
How many analysts cover CLBT?
8 analysts rate Cellebrite DI stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CLBT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts